# Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

> **NCT00121641** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1035 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Saxagliptin
- **DRUG:** Saxagliptin
- **DRUG:** Placebo matching Saxagliptin
- **DRUG:** Metformin
- **DRUG:** Placebo matching Metformin
- **DRUG:** Saxagliptin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00121641
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2006-08
- **Final completion:** 2010-02
- **Target enrollment:** 1035 (ACTUAL)
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121641, "Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00121641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*